TY - JOUR
T1 - Molecular etiology of arthrogryposis in multiple families of mostly Turkish origin
AU - Bayram, Yavuz
AU - Karaca, Ender
AU - Akdemir, Zeynep Coban
AU - Yilmaz, Elif Ozdamar
AU - Tayfun, Gulsen Akay
AU - Aydin, Hatip
AU - Torun, Deniz
AU - Bozdogan, Sevcan Tug
AU - Gezdirici, Alper
AU - Isikay, Sedat
AU - Atik, Mehmed M.
AU - Gambin, Tomasz
AU - Harel, Tamar
AU - El-Hattab, Ayman W.
AU - Charng, Wu Lin
AU - Pehlivan, Davut
AU - Jhangiani, Shalini N.
AU - Muzny, Donna M.
AU - Karaman, Ali
AU - Celik, Tamer
AU - Yuregir, Ozge Ozalp
AU - Yildirim, Timur
AU - Bayhan, Ilhan A.
AU - Boerwinkle, Eric
AU - Gibbs, Richard A.
AU - Elcioglu, Nursel
AU - Tuysuz, Beyhan
AU - Lupski, James R.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - BACKGROUND. Arthrogryposis, defined as congenital joint contractures in 2 or more body areas, is a clinical sign rather than a specific disease diagnosis. To date, more than 400 different disorders have been described that present with arthrogryposis, and variants of more than 220 genes have been associated with these disorders; however, the underlying molecular etiology remains unknown in the considerable majority of these cases. METHODS. We performed whole exome sequencing (WES) of 52 patients with clinical presentation of arthrogryposis from 48 different families. RESULTS. Affected individuals from 17 families (35.4%) had variants in known arthrogryposis-associated genes, including homozygous variants of cholinergic γ nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects). Deleterious variants in candidate arthrogryposis-causing genes (fibrillin 3 [FBN3], myosin IXA [MYO9A], and pleckstrin and Sec7 domain containing 3 [PSD3]) were identified in 3 families (6.2%). Moreover, in 8 families with a homozygous mutation in an arthrogryposis-associated gene, we identified a second locus with either a homozygous or compound heterozygous variant in a candidate gene (myosin binding protein C, fast type [MYBPC2] and vacuolar protein sorting 8 [VPS8], 2 families, 4.2%) or in another disease-associated genes (6 families, 12.5%), indicating a potential mutational burden contributing to disease expression. CONCLUSION. In 58.3% of families, the arthrogryposis manifestation could be explained by a molecular diagnosis; however, the molecular etiology in subjects from 20 families remained unsolved by WES. Only 5 of these 20 unrelated subjects had a clinical presentation consistent with amyoplasia; a phenotype not thought to be of genetic origin. Our results indicate that increased use of genome-wide technologies will provide opportunities to better understand genetic models for diseases and molecular mechanisms of genetically heterogeneous disorders, such as arthrogryposis.
AB - BACKGROUND. Arthrogryposis, defined as congenital joint contractures in 2 or more body areas, is a clinical sign rather than a specific disease diagnosis. To date, more than 400 different disorders have been described that present with arthrogryposis, and variants of more than 220 genes have been associated with these disorders; however, the underlying molecular etiology remains unknown in the considerable majority of these cases. METHODS. We performed whole exome sequencing (WES) of 52 patients with clinical presentation of arthrogryposis from 48 different families. RESULTS. Affected individuals from 17 families (35.4%) had variants in known arthrogryposis-associated genes, including homozygous variants of cholinergic γ nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects). Deleterious variants in candidate arthrogryposis-causing genes (fibrillin 3 [FBN3], myosin IXA [MYO9A], and pleckstrin and Sec7 domain containing 3 [PSD3]) were identified in 3 families (6.2%). Moreover, in 8 families with a homozygous mutation in an arthrogryposis-associated gene, we identified a second locus with either a homozygous or compound heterozygous variant in a candidate gene (myosin binding protein C, fast type [MYBPC2] and vacuolar protein sorting 8 [VPS8], 2 families, 4.2%) or in another disease-associated genes (6 families, 12.5%), indicating a potential mutational burden contributing to disease expression. CONCLUSION. In 58.3% of families, the arthrogryposis manifestation could be explained by a molecular diagnosis; however, the molecular etiology in subjects from 20 families remained unsolved by WES. Only 5 of these 20 unrelated subjects had a clinical presentation consistent with amyoplasia; a phenotype not thought to be of genetic origin. Our results indicate that increased use of genome-wide technologies will provide opportunities to better understand genetic models for diseases and molecular mechanisms of genetically heterogeneous disorders, such as arthrogryposis.
UR - https://www.scopus.com/pages/publications/84956873601
U2 - 10.1172/JCI84457
DO - 10.1172/JCI84457
M3 - Article
C2 - 26752647
AN - SCOPUS:84956873601
SN - 0021-9738
VL - 126
SP - 762
EP - 778
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -